Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-254-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.03 million
Profitability
Miscellaneous
Employees106
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions
What is Strongbridge Biopharma's stock symbol?
Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."
How were Strongbridge Biopharma's earnings last quarter?
Strongbridge Biopharma plc (NASDAQ:SBBP) announced its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.09. The biotechnology company earned $4.34 million during the quarter, compared to the consensus estimate of $4.69 million. Strongbridge Biopharma had a return on equity of 79.31% and a net margin of 227.79%. View Strongbridge Biopharma's Earnings History.
When is Strongbridge Biopharma's next earnings date?
What guidance has Strongbridge Biopharma issued on next quarter's earnings?
Strongbridge Biopharma issued an update on its FY 2019 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-20 million, compared to the consensus revenue estimate of $20.38 million.
What price target have analysts set for SBBP?
6 equities research analysts have issued twelve-month price objectives for Strongbridge Biopharma's stock. Their forecasts range from $11.00 to $18.00. On average, they anticipate Strongbridge Biopharma's share price to reach $14.6667 in the next year. This suggests a possible upside of 388.9% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.
What is the consensus analysts' recommendation for Strongbridge Biopharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.
Has Strongbridge Biopharma been receiving favorable news coverage?
Press coverage about SBBP stock has been trending neutral recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Strongbridge Biopharma earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Strongbridge Biopharma's key competitors?
Some companies that are related to Strongbridge Biopharma include Organogenesis (ORGO), Akebia Therapeutics (AKBA), Advanz Pharma (CXRXF), Crinetics Pharmaceuticals (CRNX), CannTrust (CTST), Lexicon Pharmaceuticals (LXRX), Kura Oncology (KURA), Aurinia Pharmaceuticals (AUPH), ZEALAND PHARMA/S (ZEAL), Puma Biotechnology (PBYI), Cytokinetics (CYTK), Odonate Therapeutics (ODT), TG Therapeutics (TGTX), Zymeworks (ZYME) and Obseva (OBSV).
What other stocks do shareholders of Strongbridge Biopharma own?
Who are Strongbridge Biopharma's key executives?
Strongbridge Biopharma's management team includes the folowing people:
- Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
- Mr. A. Brian Davis, Chief Financial Officer (Age 52)
- Dr. Fredric Cohen, Chief Medical Officer (Age 54)
- Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
- Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
Who are Strongbridge Biopharma's major shareholders?
Strongbridge Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (5.15%), Park West Asset Management LLC (2.44%), Opaleye Management Inc. (2.13%), Prosight Management LP (1.72%), Vivo Capital LLC (1.69%) and BlackRock Inc. (1.08%). View Institutional Ownership Trends for Strongbridge Biopharma.
Which institutional investors are selling Strongbridge Biopharma stock?
SBBP stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Park West Asset Management LLC, Broadfin Capital LLC, Tredje AP fonden, Essex Investment Management Co. LLC and Prosight Management LP. View Insider Buying and Selling for Strongbridge Biopharma.
Which institutional investors are buying Strongbridge Biopharma stock?
SBBP stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Jefferies Group LLC, Tibra Equities Europe Ltd, Morgan Stanley, Renaissance Technologies LLC, Private Advisors LLC, ExodusPoint Capital Management LP and BlackRock Inc.. View Insider Buying and Selling for Strongbridge Biopharma.
How do I buy shares of Strongbridge Biopharma?
Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Strongbridge Biopharma's stock price today?
One share of SBBP stock can currently be purchased for approximately $3.00.
How big of a company is Strongbridge Biopharma?
Strongbridge Biopharma has a market capitalization of $162.52 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.
What is Strongbridge Biopharma's official website?
How can I contact Strongbridge Biopharma?
Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]
MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
